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Lymphoid Organ Development and 
Function
Ann Ager*
Division of Infection and Immunity, School of Medicine and Systems Immunity Research Institute, Cardiff University, Cardiff, UK
The blood vasculature regulates both the development and function of secondary lym-
phoid organs by providing a portal for entry of hemopoietic cells. During the development 
of lymphoid organs in the embryo, blood vessels deliver lymphoid tissue inducer cells 
that initiate and sustain the development of lymphoid tissues. In adults, the blood vessels 
are structurally distinct from those in other organs due to the requirement for high levels 
of lymphocyte recruitment under non-inlammatory conditions. In lymph nodes (LNs) 
and Peyer’s patches, high endothelial venules (HEVs) especially adapted for lymphocyte 
traficking form a spatially organized network of blood vessels, which controls both the 
type of lymphocyte and the site of entry into lymphoid tissues. Uniquely, HEVs express 
vascular addressins that regulate lymphocyte entry into lymphoid organs and are, 
therefore, critical to the function of lymphoid organs. Recent studies have demonstrated 
important roles for CD11c+ dendritic cells in the induction, as well as the maintenance, 
of vascular addressin expression and, therefore, the function of HEVs. Tertiary lymphoid 
organs (TLOs) are HEV containing LN-like structures that develop inside organized 
tissues undergoing chronic immune-mediated inlammation. In autoimmune lesions, 
the development of TLOs is thought to exacerbate disease. In cancerous tissues, the 
development of HEVs and TLOs is associated with improved patient outcomes in several 
cancers. Therefore, it is important to understand what drives the development of HEVs 
and TLOs and how these structures contribute to pathology. In several human diseases 
and experimental animal models of chronic inlammation, there are some similarities 
between the development and function of HEVs within LN and TLOs. This review will 
summarize current knowledge of how hemopoietic cells with lymphoid tissue-inducing, 
HEV-inducing, and HEV-maintaining properties are recruited from the bloodstream to 
induce the development and control the function of lymphoid organs.
Keywords: blood vessels, high endothelial venules, peripheral node addressin, mucosal addressin, lymph nodes, 
tertiary lymphoid organs, ectopic lymphoid structures
iNTRODUCTiON
Secondary lymphoid organs (SLOs) are sites in which immune responses are initiated and main-
tained in order to generate protective immunity against exogenous pathogens and tolerance to 
self-antigens and commensal organisms (1, 2). hese specialized structures include lymph nodes 
(LNs), Peyer’s patches (PPs), tonsils, appendix, bronchus-associated lymphoid tissue (BALT), 
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nasal-associated lymphoid tissue (NALT), isolated lymphoid 
follicles, and the spleen. All SLOs develop in the embryo, apart 
from NALT and BALT, which develop neonatally and in adults, 
respectively. As well as supplying oxygen and nutrients, the 
vasculature regulates the development of SLOs by recruiting 
a distinct population of hemopoietic cells that is essential to 
initiate lymphoid organogenesis. In adults, the blood vasculature 
in lymphoid organs is diferent from that found in other organs 
due to the requirement for eicient recruitment of lymphocytes 
under non-inlammatory, homeostatic conditions. Specialized 
blood vessels called high endothelial venules (HEVs) perform 
this function in all lymphoid organs except the spleen (3).
Tertiary lymphoid organs (TLOs) are lymph node-like 
immune cell clusters that develop inside non-lymphoid organs in 
response to chronic immune-mediated inlammation stimulated 
by persistent infections, chronic grat rejection, autoimmunity, 
and cancer (4). Deining features of TLOs are those that deine 
SLOs: HEVs, lymphoid stromal cells, separate T-lymphocyte, 
and B-lymphocyte-rich compartments, follicular dendritic cell 
(FDC)-containing germinal centers, and antigen-presenting 
cells, including dendritic cells (DCs). However, in contrast to 
SLOs, TLOs are not encapsulated organs and are also known 
as tertiary lymphoid structures or ectopic lymphoid structures 
(ELS). TLOs are sites of active immune responses in autoimmune 
patients and animal models of autoimmunity (5, 6). here is evi-
dence implicating TLOs in generating destructive immunity to 
self-antigens (7) although the relative contributions of TLOs and 
SLOs to disease progression are diicult to dissect during ongo-
ing disease. Retrospective studies have correlated the presence of 
TLOs in resected solid cancers with prolonged patient outcome 
following resection of the primary cancer in several cancers (8). 
In some cancers, the density of HEVs alone predicted patient 
outcome (9, 10), indicating the critical role that HEVs play in 
orchestrating anti-cancer immunity. Importantly however, the 
formation of TLOs does not correlate with improved cancer 
patient outcome for all cancers. In virus-induced hepatic cellular 
carcinoma, TLOs promote carcinogenesis (11). In Helicobacter 
pylori-infected humans and mice, TLO development precedes 
carcinogenesis but whether TLOs promote the development 
of gastric cancer is not clear (12, 13). herefore, there is much 
interest in how HEVs and TLOs develop and their exact roles in 
diferent chronic inlammatory diseases.
he development of LNs and PPs is well characterized, but 
how TLOs form is less clear because they develop during ongoing 
diseases. he similarities in structure between SLOs and TLOs 
suggest that underlying mechanisms driving their development 
may be conserved. Much attention has focused on the role of 
hemopoietic lymphoid tissue inducer (LTi) cells in driving the 
diferentiation of local mesenchyme into lymphoid tissue organ-
izer (LTo) cells during the development of LNs and PPs in mice 
(14–16). LTo cells are gp38+ ibroblasts and are precursors of lym-
phoid stromal cells such as ibroblast reticular cells (FRCs) and 
FDCs. Lymphotoxin (LT)-αβ on hemopoietic LTi cells engaging 
lymphotoxin β receptor (LTβR) on LTo cells plays a dominant 
role in diferentiating LTo into chemokine-secreting, adhesion 
molecule expressing ibroblasts that are able to recruit and retain 
LTis in the developing lymphoid tissue. An equally important, but 
unanswered question, is how embryonic blood vessels deliver LTi 
cells from their site of generation in fetal liver to predetermined 
sites where LNs are to develop. A role for inlamed blood vessels 
in initiating TLO development is implied by the inding that 
myeloid cells recruited into inlamed tissues drive the diferen-
tiation of gp38+ ibroblasts that share properties with lymphoid 
stromal cells and are likely precursors of LTo cells (17). However, 
the mechanisms underlying myeloid cell recruitment by inlamed 
blood vessels were not determined in this study.
In adults, HEVs continually recruit naive and memory 
lymphocytes from the bloodstream into lymphoid organs in 
an antigen-independent manner where they survey DCs for 
cognate antigen (3). In peripheral LN draining the skin, HEVs 
express the peripheral addressin, peripheral node addressin 
(PNAd), whereas in PPs, HEVs express the mucosal addressin, 
mucosal addressin cell adhesion molecule (MAdCAM)-1. HEVs 
in some LNs (mesenteric, sacral, cervical) express both PNAd 
and MAdCAM-1. It has long been known that PNAd expres-
sion by HEV is actively maintained since PNAd levels on HEVs 
are rapidly downregulated following disruption of, or isolation 
from, the lymphoid microenvironment (18–20). Interestingly, 
HEVs in peripheral LN of newborn mice express the mucosal 
addressin but not the peripheral addressin (21, 22). During 
the irst 2–3  weeks of life, HEV maturation is completed by a 
switch in vascular addressin expression from MAdCAM-1 to 
PNAd. How the vascular addressin switch is regulated and PNAd 
expression maintained on HEV in adult SLOs have been unclear. 
Recent studies have identiied critical roles for CD11c+ DCs in 
the vascular addressin switch (23) as well as the maintenance of 
PNAd-expressing HEV in adult mice (24). herefore, the blood 
vasculature plays a central role in recruiting distinct populations 
of hemopoietic cells at precise stages of lymphoid organ develop-
ment that are essential to initiate lymphoid organogenesis, induce 
HEV maturation, and maintain fully diferentiated HEV. hese 
points will be addressed in greater detail in the following section.
A key step in the recruitment of lymphoid cells is their selec-
tion from the total pool of blood-borne leukocytes by binding 
to the inner blood vessel surface prior to transmigration across 
the vessel wall and entry into lymphoid organs. his involves a 
sequence of adhesive interactions between leukocytes and vascu-
lar endothelial (VE) cells, which can be divided into distinct stages 
of rolling and activation-induced arrest. In general, selectins 
mediate rolling and chemokines immobilized on the endothelial 
cell (EC) surface activate leukocyte integrins to arrest rolling 
cells. How hemopoietic cells with LT-inducing, HEV-inducing, 
and HEV-maintaining properties are recruited into lymphoid 
organs is central to understanding both the development of lym-
phoid tissues and the mechanisms regulating adaptive immune 
responses and disease pathologies.
BLOOD veSSeLS AND THe 
DeveLOPMeNT OF SLOs
he earliest event in LN development is the formation of 
lymphatic vasculature around embryonic day 10.5 (E10.5) by 
budding from larger veins and establishing a primordial lymph 
sac or anlagen (Figure  1) (25). CD45+ CD4+ CD3− IL7Rα+ 
FiGURe 1 | Blood vessels and high endothelial venules (Hevs) in the development of lymph nodes (LNs). Top: LN development represented as relative 
sizes of (left) embryonic and (right) neonatal and adult LNs. Middle (left): in the embryo, neuronal stimulation induces retinoic acid-dependent expression of CXCL13 
by mesenchymal cells that can be reverse transcytosed and presented on the inner surface of embryonic blood vessels. (Right) In LNs of adults, the HEV network 
extends from the cortical/paracortical junction adjacent to B cell follicles to large collecting veins in the hilar region gradually increasing in diameter from the smallest, 
order V venules to the largest order I venules (left hand inset). HEV connect directly to afferent lymphatics via ibroblast reticular cell-coated conduits that form the 
supporting internal scaffold on which lymphocytes and antigen presenting cells crawl during  immunosurveillance (right hand insert). This enables the recruitment of 
fetal liver-derived CXCR5+ α4β7 integrin-expressing lymphoid tissue inducer cells to the sites where LN develop. (Right) At birth, structurally distinct MAdCAM-1-
expressing HEV lined with cuboidal endothelial cells and supported by a thickened ibronectin containing basal lamina are visible. During the irst weeks of life, 
MAdCAM-1-expressing HEV recruit CD11c+ neonatal migratory dendritic cells mobilized from the intestinal lamina propria, undergo a switch from MAdCAM-1 to 
peripheral node addressin expression and become ensheathed by ibroblast reticular cells. The vascular addressin switch is followed by rapid growth and a 
concomitant increase in cellularity and expansion in LN.
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RORγt+, Id2+ lymphoid tissue-inducing (LTi) cells (members 
of the group 3 category of innate lymphoid cells) are recruited 
into the anlagen and drive the development of gp38+ LTo cells 
from local mesenchyme (26). CXCL13 and IL7, produced by 
local mesenchymal ibroblasts in response to retinoic acid (RA) 
generated by neuronal stimulation, recruit CXCR5 and IL7 
receptor-expressing LTi cells at sites where LNs are to develop 
(14). In the embryonic intestine, myeloid cell expression of the 
tyrosine kinase receptor, RET, is important to localize LTi to sites 
where PPs develop (27). LTαβ is upregulated on the surface of 
incoming LTis and stimulates LTβR-dependent upregulation of 
MAdCAM-1, vascular cell adhesion molecule (VCAM)-1, and 
intercellular adhesion molecule (ICAM)-1 and the secretion of 
homeostatic chemokines CXCL13, CCL19, and CCL21 by lym-
phoid stromal LTo cells. his enables LTo cells to retain recruited 
LTi cells in the developing anlagen. he continual recruitment 
and retention of LTi cells during embryogenesis is required to 
diferentiate suicient numbers of LTo cells to support the full 
development and organization of LNs and PPs (22).
During embryogenesis, LTi cells are generated in the fetal 
liver so how are they recruited to the sites at which LNs and PPs 
are to develop? A key inding is that all embryonic venous blood 
vessels express MAdCAM-1 (28). LTis express the integrin α4β7, 
which binds to MAdCAM-1 and α4β7-MAdCAM-1 binding is 
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a dominant pathway for leukocyte recruitment from the blood-
stream into developing LNs (21). In adults, homeostatic and 
inlammatory chemokines released by stromal cells are reverse 
transcytosed and presented on the inner blood vessel surface 
using Dufy antigen-related receptor-dependent and independ-
ent pathways (29–32). By analogy, CXCL13 released by activated 
ibroblasts presented on the inner surface of embryonic blood 
vessels together with cell surface MAdCAM-1, recruits CXCR5 
expressing LTis from the bloodstream to initiate lymphoid 
organogenesis. Key questions, therefore, are what controls 
MAdCAM-1 expression on blood vessels in the embryo and is 
MAdCAM-1 essential for lymphoid organogenesis? MAdCAM-1 
is expressed by all venous blood vessels as early as E9.5 in mice 
and expression is maintained throughout lymphoid organo-
genesis (28). In adults, MAdAM-1 expression by cultured EC is 
induced by classical Rel A/NF-κB signaling stimulated by factors 
such TNF-α, LT-α, IL-1-β, and LPS (33–35). Whether constitu-
tive MAdCAM-1 expression on blood vessels in the LN anlagen 
is driven by NF-κB signaling or is ontologically determined, for 
example, by the transcription factor NKX2.3 (36), has not been 
determined. Interestingly, MAdCAM-1 expression by embry-
onic blood vessels is not essential for lymphoid organogenesis 
since LNs and PPs develop in MAdCAM-1 ko mice (37). LTis 
also express α4β1 integrin, which binds to VCAM-1 and could 
substitute for MAdCAM-1, however, mice globally deicient in 
VCAM-1 die in utero (38) and the role of VCAM-1 in lymphoid 
organogenesis is undetermined. ICAM-1 expression by LTo cells 
is not essential for lymphoid organogenesis since LNs develop in 
ICAM-1-deicient mice (39). However, MAdCAM-1, VCAM-1, 
and ICAM-1 are not redundant in adult mice because they regu-
late lymphocyte recirculation through SLOs and/or recruitment 
to inlamed tissues (1, 3).
Lymph nodes and PPs do not develop in LTα ko mice (40). 
Administration of an LTβR agonist to pregnant mice bypasses the 
requirement for LTi cells and induces LN development (41). he 
initiation of LN and PP organogenesis is time restricted; mesen-
teric LN starts around E9–10 and PPs around E16 with peripheral 
LN (axillary, brachial, inguinal, and popliteal) between E10 and 
E16. However, exogenous administration of LTβR agonists out-
side of these times will not initiate LN formation. Administration 
of antagonistic LTβR-Ig to pregnant wildtype mice also blocks 
the development of LN in a similar time-dependent manner (42). 
What controls the timing of LN development is not clear but one 
possibility is the ability of embryonic blood vessels to recruit 
LTi cells. For example, the expression of suicient MAdCAM-1, 
immobilized chemokines, or other, as yet unidentiied, homing-
associated molecules that recruit LTi cells from the bloodstream 
into to the LN anlagen may be time dependent. he local genera-
tion of RA drives lymphoid organogenesis and RA is required to 
mature developing blood vessels in the embryo (43). It is possible 
that locally generated RA facilitates LTi recruitment by promot-
ing the expression or activity of homing-associated molecules on 
growing vessels in the LN anlagen, but we know very little about 
when RA is produced and how this is regulated.
Although LTαβ–LTβR is a dominant NF-κB signaling path-
way and CXCL13 a dominant chemokine in the development of 
peripheral LN and PP, other pathways can substitute during the 
development of mucosal and visceral draining LN. For example, 
mesenteric, cervical (submandibular), sacral, and lumbar LN (44) 
develop in LTβ-, LTβR-, or CXCL13-deicient mice (15, 22). LTβR 
engagement by membrane LTαβ stimulates both classical NF-κB 
signaling via Iκκβ and p50/RelA as well as non-classical signal-
ing via Iκκα and p52/RelB, and there is considerable interplay 
between these two pathways (45). LN and PP do not develop in 
mice globally deicient in either RelA or Rel B, key components 
of classical and non-classical NF-κB signaling, respectively, 
although the impact of classical NF-κB signaling on LN develop-
ment may be via upregulation of non-classical NF-κB signaling 
substrates such as NF-κB2 and RelB (46, 47). In mice deicient 
in NFkB2, the substrate for p52 in the non-classical pathway, 
mesenteric and some peripheral LN develop but lymphoid organs 
that form later in embryogenesis (inguinal, popliteal, and PPs) are 
small or do not develop at all (48). It is suggested that p50/RelB 
can substitute for p52/RelB in these mice but the signal strength 
is weaker and so, although LTi cells are recruited, the induction 
of CAMs is not enough to retain suicient LTi cells to maintain 
development and organize the full structure of late developing 
lymphoid organs. Non-classical NF-κB signaling is important 
for the proper development of HEVs since the small LN that 
develop in LTβ- or NFkB2-deicient mice have poorly developed 
HEVs, as do peripheral LNs that develop in mice expressing a 
signaling-deicient mutant of the non-classical NK-κB pathway, 
Iκκα (48, 49). he widespread expression of LTβR on the develop-
ing vasculature as well as LTo cells makes it diicult to assess their 
relative contributions to the development of lymphoid organs 
or of HEVs in mice globally deicient in either LTαβ–LTβR or 
following administration of antagonistic LTβR-Ig. Recent studies 
have shown that the development of peripheral LNs in 25–40% of 
pups is completely blocked in mice selectively deicient in LTβR 
in blood and lymphatic ECs, but the underlying mechanism is 
not clear (50). Further work will be required to dissect the roles of 
NF-κB signaling in the blood vs the lymphatic vasculature during 
lymphoid organogenesis and how this integrates into the scheme 
of lymphoid organogenesis driven by gp38+ lymphoid stromal 
LTo cells.
THe DeveLOPMeNT AND FUNCTiON OF 
HiGH eNDOTHeLiAL veNULeS iN SLOs
The vascular Addressin Switch
he recruitment of naïve T and B cells into all lymphoid organs, 
apart from spleen, is dependent on the diferentiation of a subset 
of blood vessels into HEVs. Structurally distinct HEVs are not 
apparent in LN of mice until birth when a branching network 
of HEV blood vessels starts to organize around B cell follicles 
during the irst days ater birth in PPs (28). A key event in 
neonatal maturation and expansion of LN is a switch in vascular 
addressin expression by HEV (21). In LNs of newborn mice, 
all HEVs express the mucosal addressin MAdCAM-1; during 
the irst few weeks of life MAdCAM-1 is downregulated and 
expression of the PNAd is upregulated. PNAd comprises a mix-
ture of ligands for L-selectin (CD34, podocalyxin, GlyCAM-1, 
MAdCAM-1, nepmucin, and endomucin) that are modiied 
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by 6-sulfo sialyl Lewisx on extended core 1 O-linked oligosac-
charides and detected by monoclonal antibody MECA79 (51). 
PNAd expressed on the inner, apical surface of HEVs co-operates 
with the arrest chemokine CCL21 to select L-selectin/CD62L+, 
CCR7+ lymphocytes from the bloodstream for entry into LN 
allowing postnatal colonization of LN by naive T and B lympho-
cytes as they are released into the circulation from the thymus 
and fetal liver/bone marrow, respectively. Interestingly, PNAd is 
also expressed on the basolateral surfaces of ECs lining HEVs 
but it is not involved in recruiting lymphocytes directly from 
the bloodstream. Distinct sulfotransferases generate apical and 
basolateral PNAd and the expression of GlcNAc6ST-2 (HEC-6ST; 
CHST4), which is required to generate apically expessed PNAd, 
is restricted to HEV ECs, whereas GlcNAc6ST-1 (CHST2), which 
generates basolaterally expressed PNAd, is more widely expressed 
in stromal cells (51). he PNAd-expressing HEV network grows 
alongside the growth of other stromal components resulting in 
a rapid increase in the size and cellularity of LN during the irst 
weeks of life (23). Although PNAd is a well-characterized ligand 
for L-selectin, it only accounts for 50% of L-selectin-dependent 
recruitment into peripheral LNs. Important non-PNAd ligands 
on HEV that regulate L-selectin-dependent recruitment into 
peripheral LN include 6-sulpho sialyl Lewis X modiied N-linked 
glycans such as CD34, as well as a minor role for core 2-branched 
O-linked glycans (51, 52).
Vascular addressins expressed on the inner, luminal surface 
of ECs lining HEV bind to homing receptors on lymphocytes; 
therefore, addressins deine the specialized property of HEV 
in driving lymphocyte recruitment into LNs and PPs. PNAd 
was originally described in HEVs of peripheral LNs draining 
the skin (inguinal, axillary, brachial, and popliteal) (53) and 
MAdCAM-1 in mucosal-associated lymphoid tissues such as PPs 
(54). However, analysis of other mucosal and viscera-draining 
SLOs in mice shows that PNAd expression is upregulated and 
MAdCAM-1 variably downregulated. For example, MAdCAM-1 
expression is not completely downregulated in mesenteric and 
sacral LNs where individual high endothelial cells (HECs) co-
express PNAd and MAdCAM-1. However, mucosal addressin 
is completely downregulated in lymphoid tissues draining other 
mucosal sites such as cervical (submandibular) LN or NALT 
(4). Similarly, LNs draining visceral organs, such as lumbar LN, 
express PNAd and not mucosal addressin (44); therefore PNAd 
expression is not restricted to subcutaneous LN and is widely 
expressed by mucosal and visceral LN in mice. PNAd expression 
was originally reported to be restricted to the basolateral surfaces 
of HEVs in PPs (54). However, in diferent mouse strains and 
other species, PNAd expression in PPs is comparable with that in 
peripheral LN, which may relect increased antigenic stimulation 
(51). Why MAdCAM-1 expression is maintained by HEVs in PPs 
and some mucosal LN whereas other HEVs completely switch 
to PNAd expression is not clear, but MAdCAM-1 expression is 
regulated by the transcription factor NKX2.3 (55).
The Connection with Afferent Lymph
A unique feature of HEV is the connection with aferent lymph. 
HEVs are supported by a perivascular sheath composed of FRCs 
that are connected to the FRC coated conduit system within LN. 
he conduit system allows communication between aferent 
lymph and HEV whereby incoming lymph-borne soluble factors, 
such as chemokines and cytokines, are delivered directly to the 
basal lamina of HEV (Figure 1) (56). Early studies showed that 
ligation of aferent lymphatics, which drain luid and immune cells 
into popliteal LN, resulted in a gradual lattening of HECs and 
although some PNAd expression was retained it was restricted 
to the basolateral surfaces of HECs (18, 19, 57). Other changes 
in HECs included a transient induction of MAdCAM-1 expres-
sion, which peaked 4 days following deaferentization suggesting 
reversion of mature HEVs to an immature state. Lymphocyte 
recruitment by HEV decreased and was no longer detectable 
8 days ater deaferentization. HEVs reverted to fully functional 
vessels expressing PNAd at the luminal surface following regrowth 
of aferent lymphatics demonstrating the complete reversibility of 
HEV diferentiation. Early studies indicated a dominant role for 
LTβR signaling in maintaining PNAd expression since chronic 
administration of LTβR blocking reagents to adult mice recapitu-
lates the efects of deaferentization in that HEVs downregulate 
PNAd and MAdCAM-1, and therefore lose the ability to support 
lymphocyte homing (58). he lattened appearance of PNAd-
positive HEV in deaferentized LNs is seen in peripheral LNs 
that develop in mice in the absence of endothelial expression of 
LTβR (50) and in inguinal LNs developing in the absence of either 
NFKB2 or IKKα (48, 49), indicating a key role for LTβR stimulated 
non-canonical NFκB signaling in driving luminal expression of 
PNAd by HECs. Which cells engage LTβR on HECs to induce 
and maintain PNAd expression has been unclear, however, recent 
studies identify dominant roles for CD11c+ DCs in the induction, 
as well as the maintenance, of PNAd expression by HEV.
Role of CD11c+ Cells in the vascular 
Addressin Switch
An important inding is that during the irst weeks of life CD11c+, 
CD11b+, CD103+ DCs mobilized from the gut lamina propria 
in response to microbial colonization induce the switch from 
mucosal to peripheral addressin expression by HEV in peripheral 
LN (23). RA-dependent signaling is critical for these so-called 
neonatal migratory DCs to induce the vascular switch; cells that 
do not express retinaldeyhde dehydrogenase (RALDH), which 
generates RA from retinaldehyde, a derivative of Vitamin A, are 
unable to induce the vascular addressin switch. his important 
inding came from studies of adult germ-free mice in which 
peripheral LN HEVs express MAdCAM-1, but not PNAd, and 
LN are small without clear compartmentalization into T and 
B-cell areas, similar to LN in newborn mice. When germ-free 
mice were co-housed with conventionally housed mice, HEVs 
underwent the vascular addressin switch with consequent 
increases in lymphocyte homing and LN cellularity. hese efects 
could be reproduced by administration of RALDH+ neonatal 
migratory DCs isolated from conventionally housed adult mice 
to young germ-free mice. Migration of neonatal migratory DCs 
to peripheral LN was dependent on MAdCAM-1 expression by 
HEVs in peripheral LN. Interestingly, the migration of these 
cells to peripheral LN was highest around 2  weeks ater birth 
and subsided ater 6  weeks, presumably because of the loss of 
MAdCAM-1 expression by peripheral LN HEVs.
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In adult mice, CD11c+ cells have been shown to maintain 
PNAd-expressing, fully functional HEVs by stimulating LTβR-
dependent signaling in HECs (24, 50). Moussion and Girard 
used transgenic mice expressing the diphtheria toxin (DT) 
receptor under the CD11c promoter (CD11c-DTR mice) and 
DT to deplete CD11c+ cells (24). hey noted a gradual loss of 
PNAd expression, a transient expression of MAdCAM-1, and a 
reduction in lymphocyte entry via HEVs over 8 days, which was 
prevented by administration of exogenously generated LTαβ-
expressing CD11c+ DCs. Since ligands for LTβR are membrane 
bound, LTαβ DCs might be expected to make frequent contacts 
with HECs under homeostatic conditions in order to maintain 
PNAd expression. Migration of DCs into LN of adult mice has 
focused on entry from surrounding tissues via incoming, aferent 
lymphatics. DCs entering via this route do not come into cellular 
contact with HECs since they do not penetrate the surrounding 
pericytic sheath (59, 60). However, DCs entering from sur-
rounding tissues via aferent lymphatics do locate around HEVs 
(61); it is therefore possible that protruding DC membranes or 
exosomes released by DC (62, 63) could cross the pericytic sheath 
and contact with HECs. Precursors of classical DCs that are 
recruited from the bloodstream into LN of adult mice spend up 
to 5 h in the walls of HEVs are a possible HEV-maintaining cell. 
In this scenario, the critical role of aferent lymph in maintaining 
fully diferentiated HEVs is not as an entry point for DCs but to 
supply the chemoattractants necessary to recruit LT-expressing 
DCs from the bloodstream, enabling DC-HEC contact to sustain 
LTβR signaling.
Interestingly, CCR7+ expression by CD11c+ cells is required 
to control the homeostatic expansion of PNAd-expessing HEV 
but in the absence of CCR7 expession, CD11c+ cells are still able 
to induce the switch in addressin expression to PNAd (64). he 
increase in size of the HEV network and associated increase 
in LN cellularity and volume is due, in part, to the release of 
angiogenic stimuli such as VEGF-A by FRC and DCs (65, 66). 
hese indings suggest that the diferentiation of fully functional, 
PNAd-expressing HEV and the expansion of the HEV network 
are controlled by diferent types of CD11c+ cells in adult mice. It 
will be interesting to determine whether RA signaling is required 
for CD11c+ DCs to maintain PNAd expression and expand HEV 
in adult mice as has been shown in neonates (23).
High endothelial venules in Homeostatic 
Lymphocyte Traficking
Together, the SLOs are uniquely placed to survey the whole 
body for incoming pathogens and self-antigens derived from 
the skin, mucosal surfaces, or directly into the bloodstream, 
mount an appropriate immune response and clear invading 
pathogens from the body. To achieve this, rare lymphocytes with 
appropriate antigen receptor must be selected from the total 
pool of lymphocytes each with its own unique receptor; this 
occurs inside SLOs. Pathogens are irst degraded and presented 
as MHC-binding peptides on DCs bound to gp38+ FRCs. he 
total pool of lymphocytes in the body is then exposed to patho-
gen peptide-enriched DCs. Lymphocytes with antigen receptors 
able to respond to the level of peptide presented are removed 
from the circulating pool of cells and undergo proliferation and 
diferentiation to efector, memory, or regulatory lymphocytes 
before returning to the circulation. Blood vessels are critical 
components of adaptive immunity since they recruit naïve and 
central memory lymphocyte irrespective of antigen receptor 
speciicity and deliver them to DCs inside lymphoid organ under 
homeostatic conditions. Postcapillary venules (PCV) lined with 
continuous ECs are the preferred sites of lymphocyte extravasa-
tion in LNs and other organs such as the skin and GI tract. he 
increase in diameter as blood vessels transition from capillaries 
to PCV alters hemodynamics such that leukocytes move to the 
outer stream or margin of lowing blood adjacent to the inner 
surface of the vessel (67). Here lymphocytes tether, roll, and arrest 
on the inside surface without obstructing low that would happen 
in smaller capillaries. In other organs where the microvessels are 
lined with sinusoidal endothelium, such as the spleen, liver, and 
bone marrow, shear stress at the vessel wall–blood interface may 
be signiicantly reduced that the requirement for selectins for 
capture from lowing blood is not necessary and other homing-
associated molecules such as leukocyte integrins perform this 
role (67). In LNs and PPs, the traicking of naïve lymphocytes is 
restricted to specialized postcapillary venules called HEVs. hese 
vessels are structurally adapted to support large-scale lymphocyte 
traicking without compromising vascular integrity. he spleen 
does not have HEV and, in mice, lymphocytes enter the spleen 
from capillaries in the marginal zone using incompletely deined 
molecular recognition pathways. he structure of human spleen 
difers from that in mice and the route of lymphocyte entry has 
not been identiied (68).
Arteries feeding the LN enter at the hilar region and arborize 
into nutrient- and oxygen-transporting capillary beds surround-
ing B cell follicles in the outer cortex and in the T cell zone. 
he capillary beds lead directly (or indirectly via arteriovenous 
shunts) into the postcapillary venular network, which extends 
throughout the paracortex (T cell area) of the LN; HEVs form 
part of this postcapillary network (Figure 1). HEVs are readily 
distinguished from other blood vessels; the cuboidal (high) ECs, 
which line HEV and give these vessels their name, contrast with 
lat ECs lining other vessels. In addition, HEVs are supported by 
a thickened basal lamina comprising overlapping pericytes and 
a perivascular sheath of FRC that together generate a structural 
and functional unit exquisitely adapted to support high levels 
of lymphocyte recruitment and transendothelial migration 
to deliver lymphocytes to the LN parenchyma. he ECs lining 
HEVs express a number of pan-endothelial markers such as 
VE-cadherin and CD31 as well as the master venous regulator 
Nr2f2 (69), which suggests that they diferentiate from local post-
capillary venules. Invitavital imaging of lymphocyte recruitment 
allows HEVs to be ordered according to size and location. he 
smallest vessels (order V) are found at the junction between the 
B cell-enriched cortex and the T cell-enriched paracortex. HEVs 
gradually increase in size to larger vessels (order II) at the junction 
between the paracortex and medulla where they merge into order 
I collecting venules which drain into hilar vein (70) (Figure 1). 
he majority of lymphocytes recruited into LN and PPs are 
from the higher order vessels III–V. In peripheral LN, L-selectin 
dependent recruitment from lower order vessels does occur but 
the vascular ligand on HEC is distinct from PNAd (71). How this 
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complex branching network of diferentiated HEVs develops and 
is maintained in LN is not clear but it is likely to be connected 
with development of the highly organized secondary structures 
of FRC-coated conduits that connect the draining lymphatics 
with the HEVs (29). he dominant roles of LTβR signaling in 
maintaining fully diferentiated PNAd-expressing HEVs as well 
as T/B compartmentalization in LNs are likely to cooperate in 
forming an organized HEV network.
he ability to image the behavior of leukocytes inside post-
capillary venules using intravital microscopy has identiied the 
molecular interactions between lymphocytes and HEVs in LN 
and PPs that control recruitment from lowing blood. he multi-
step adhesion cascade describes the sequence of tethering, rolling 
and activation-induced arrest, which selects lymphocytes for 
transendothelial migration and entry into lymphoid organs. he 
cascade is best exempliied by the fact that neutrophils undergo 
L-selectin-depending rolling in HEVs but they are unable to 
undergo activation-induced arrest by CCL21 immobilized on the 
inner HEV surface because they do not express CCR7 and are, 
therefore, not recruited into LN under homeostatic conditions 
(70). he selectin, chemokines, and integrins that regulate roll-
ing and activation-induced arrest of naive and central memory 
T and B cells and the non-random recruitment of T and B 
lymphocytes in HEV of LN and PP of mice have been described 
in detail elsewhere (1, 3, 72–74). he regulated expression of 
peripheral node and mucosal addressins by HEV and their roles 
in lymphocyte recruitment are conserved in LNs of larger animals 
as well as humans indicating that studies in mice have clinical 
relevance (75–79). his review will summarize recent advances 
in understanding the structure and function of HEV and its role 
in regulating adaptive immunity.
In LNs, L-selectin mediates tethering and rolling of lympho-
cytes. In comparison with T cells, B cells express lower L-selectin 
and are reduced in LNs but highly enriched in PPs. Although 
L-selectin supports lymphocyte rolling in HEVs of PPs, it is not a 
dominant homing molecule under homeostatic conditions since, 
in contrast to peripheral LN, the cellularity of PPs in L-selectin 
deicient mice is not reduced (80). he B-cell expressed lectin that 
supports preferential recruitment by HEVs of PPs was unknown 
until a detailed comparison of transcriptomes expressed by HECs 
isolated from PPs and peripheral LN of mice demonstrated 
preferential expression of the enzyme β-galactoside α-2,6-
sialyltransferease I (ST6GaI 1) by PP HECs. ST6Gal 1 generates 
high ainity α-2,6-sialylated glycan ligands for the B cell lectin 
CD22 (Siglec-2) and was shown to function as a B cell selective 
mucosal addressin in PPs (69).
Apart from addressin expression and their location inside 
LN, a characteristic histological feature of HEV is lymphocytes 
embedded in the walls of HEV, which suggests that transmigra-
tion is a rate-determining step in lymphocyte recruitment from 
the bloodstream into the LN parenchyma. Transmigration is 
a rapid event taking 3  min to cross the endothelial lining and 
10 min to complete migration across the underlying basal lamina 
(81–83). he molecules and signaling pathways that regulate 
transmigration are not completely understood. Whether lym-
phocytes move through the junctions between HECs (paracel-
lular route) or penetrate the EC cytoplasm (transcellular route) 
has long been debated (84, 85). It is important to understand how 
lymphocytes transmigrate the walls of HEV since the potential 
for bi-directional signaling in lymphocytes and HECs may prime 
transmigrating lymphocytes for interstitial motility and immuno-
surveillance. Recent studies have demonstrated that lymphocytes 
are held in the so-called HEV pockets that are extracellular spaces 
between HECs and the surrounding pericyte-containing basal 
lamina (86). he accumulation of transmigrating lymphocytes, 
particularly T cells, contributes to the height of HECs (81, 87). 
Residence in HEV pockets provides an opportunity for cellular 
contacts with HECs or with other transmigrating cells, such as 
DCs, which may facilitate rapid transmigration in comparison 
with vessels lined with lat EC (81). It is also possible that antigen 
could be passed from the basolateral adjoining conduits to DCs 
inside HEV pockets for presentation to incoming lymphocytes. 
HEVs are contractile vessels responding to locally released 
vasoactive agents (88). Arterial pressure and vasoconstriction 
can regulate the height of HECs measured in histological sec-
tions of LN (89). Dynamic changes in shear stress at the vessel 
wall interface generated by HEV contractility may enhance the 
capture of lymphocytes from lowing blood.
Lymphocytes form very close, intercellular, gap-like junc-
tions of 2–4 nm with HECs during transmigration (90), which 
may be the in vivo equivalent of the docking structures between 
lymphocytes and ECs reported in vitro (91, 92). ECs lining HEVs 
express a range of junctional proteins that are found in other 
vascular beds, including VE-cadherin, CD31, JAM-A, JAM-B, 
JAM-C, and ESAM-1 (93). Engagement of EC junctional pro-
teins by complementary receptors on lymphocytes may regulate 
migration across the endothelial lining of HEVs, as shown for 
leukocytes transmigrating inlamed blood vessels (67). Unlike 
other types of endothelium, HEV ECs lack tight junctions and 
vascular speciic claudin-5. hese distinct structural features 
may facilitate paracellular transmigration of lymphocytes and/or 
lymphocyte accumulation inside HEV pockets.
Some progress has been made in dissecting the molecular 
events driving entry and exit of lymphocytes from HEV pockets 
and subsequent penetration of the underlying basal lamina to 
enter the LN parenchyma (94). Lymphocytes are retained in HEV 
pockets of FTY720 treated mice, and this was thought to be due 
to lack of space in the LN parenchyma (86). However, as well as 
blocking lymphocyte exit from LN via lymphatics, FTY720 inhib-
its T cell recruitment from the bloodstream across HEVs (95). An 
alternative explanation is that incoming T cells drive the exit from 
HEV pockets and, in the absence of incoming T cells in FTY720 
treated mice, lymphocytes do not complete transmigration, as has 
been shown in vitro (96). here are other mechanisms controlling 
lymphocyte retention in HEV pockets. T cells accumulate in the 
endothelial lining of HEVs in mice treated with dual speciicity 
MMP/ADAM inhibitors (87), suggesting that exit from HEV 
pockets may be metalloproteinase-dependent. L-selectin is 
proteolytically cleaved from T cells as they transmigrate HEVs 
(97) and lymphocytes expressing a metalloproteinase-resistant 
mutant of L-selectin take longer to transmigrate the endothelial 
lining of HEVs (98). Proteolytic shedding of L-selectin following 
cross-linking by basolaterally expressed ligands such as PNAd 
may polarize transmigrating T cells, as recently demonstrated in 
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monocytes (99) and neutrophils (100) and allow directed migra-
tion into the LN parenchyma in response to HEC-derived lipids 
such as autoaxin and lymphoid stromal cell-derived chemokines 
such as CCL19 and CCL21 (101, 102).
The impact of immunization and infection 
on High endothelial venules
here are marked changes to HEVs in LNs draining sites of 
immunization or infection. hese include increased blood low, 
expansion of the HEV network, and marked changes in expres-
sion of homing-associated molecules. Changes in HEV function 
cooperate to alter the size and composition of the leukocyte 
iniltrate. In particular, altered expression of homing molecules 
on HEV enables the recruitment of activated lymphocytes and 
innate immune cells that are normally excluded by HEVs because 
they lack expression of L-selectin or CCR7. he impact of altered 
immune cell recruitment via HEV on ongoing immunity is only 
just starting to be analyzed (94).
Innate immune cells remodel feeding arterioles to increase 
blood supply and, thereby, increase the delivery of naïve lympho-
cytes into draining LNs (103). his allows a major fraction of the 
full repertoire of lymphocytes to pass through antigen-activated 
LNs within a few days (104). he HEV network grows to accom-
modate the increase in blood supply and the accompanying 
increase in lymphocyte traicking. For example, the total length 
of HEVs increases threefold from approximately 10–30  cm in 
antigen-reactive LN in parallel with a threefold size increase of LN 
volume (105). LT and VEGF family members regulate expansion 
of the HEV network. LTβR activation of FRCs by DCs induces 
release of VEGF-A, an angiogenic factor that stimulates HEV 
growth (65, 106). VEGF-A is also produced by activated DCs, 
which, following injection into the skin, stimulate the growth of 
HEV in LN draining the site of injection (66).
Other changes to HEV in antigen-challenged LN relate directly 
to links with aferent lymphatics. For example, the plasticity of 
HEV revealed by aferent lymphatic ligation (19) or isolation 
from the LN environment (20) is directly relevant to adaptive 
immune responses. Antigen administration is accompanied by a 
temporary shutdown of aferent lymphatics between days 2 and 
5 and concomitant dediferentiation of HEV (107). Interestingly, 
the loss of luminal PNAd by HEV following antigen administra-
tion is accompanied by transient induction of MAdCAM-1 as 
found following deaferentization or CD11c+ cell depletion. By 
limiting the inlux of lymphocytes, the loss of PNAd expres-
sion may serve to prevent the dilution of lymphocytes already 
in contact with antigen-laden DCs and promote the generation 
of memory cells. he reversion of PNAd-expressing HEV to 
MAdCAM-1-expressing HEV may allow entry of LTis or other 
α4β7 integrin-expressing innate lymphoid cells (108), for repair 
or remodeling of LN during the later stages of virus infection to 
restore preinfection architecture (109).
Vascular changes in antigen-stimulated LNs are accompanied 
by increased growth of aferent lymphatics and remodeling of the 
FRC network that alters the availability of chemokines for pres-
entation by HEVs. For example, the dramatic reduction in CCL21 
and CXCL13 expression by LN stroma following viral or bacte-
rial infection (110) impacts on T and B lymphocyte recruitment 
since stromal cell-derived chemokines are presented by HEVs to 
blood-borne lymphocytes (32). he increased delivery of DCs 
and other immune cells mobilized from inlamed tissues via 
expanded aferent lymphatics may have, as yet unexplored, efects 
on HEV function. However, as the immune response subsides, 
CD11c+ cells are required to remodel the perivascular FRC sheath 
surrounding HEVs and restore vascular permeability and HEV 
function (111). hese observations suggest a regulatory loop 
based on HEV that controls the size of LN, preventing uncon-
trolled growth of inlamed lymphoid tissue. How the structure 
of LNs and other secondary lymphoid tissues is restored to the 
preactivated state is largely unknown. his is likely to be relevant 
to understanding TLOs that develop in chronically inlamed 
tissues.
BLOOD veSSeLS, HiGH eNDOTHeLiAL 
veNULeS, AND THe DeveLOPMeNT OF 
TLOs
Tertiary lymphoid organs or ELS develop inside non-lymphoid 
organs. TLOs form in response to chronic immune-mediated 
inlammation stimulated by persistent antigens such as infection, 
allograt rejection or ulcerative colitis but also in several autoim-
mune conditions such as rheumatoid arthritis and Hashimoto’s 
thyroiditis (112). TLOs have been reported by histology in biop-
sied or surgically removed clinical tissues from the majority of 
organs in the body including the CNS and atherosclerotic aorta. 
TLOs are also found associated with cancerous tissues. TLOs are 
highly organized lymph node-like structures containing discrete 
T and B-cell rich areas supported by stromal cells that share mark-
ers with FRCs and FDCs in LNs. TLOs contain PNAd-expressing 
blood vessels that resemble structurally distinct HEV in LNs; 
they are the presumed sites of entry of blood-borne lymphocyte 
and, therefore, critical to the function of TLOs. PNAd-expressing 
blood vessels lined by lat ECs are found inside cancer-induced 
ectopic lymphoid aggregates that are not organized into distinct 
T/B cell areas. hese could represent immature HEV-containing 
structures in the process of forming TLOs, or TLOs that are dis-
tintegrating during the resolution of chronic inlammation (113). 
Interestingly, PNAd-expressing blood vessels that form follow-
ing depletion of Foxp3+ regulatory T cells from cancer-bearing 
mice are not associated with histologically distinct, lymphoid 
cell aggregates (114) which indicates that HEV neogenesis can 
precede lymphoid neo-organogenesis. he development of 
HEV in the absence of full-blown TLOs correlates with cancer 
regression in this experimental model highlighting the important 
role of HEV in controlling immunity to cancers. Interestingly 
gp38+ (podoplanin) stromal cells are induced locally by CD11b+ 
myeloid cells recruited to inlamed skin of mice, recapitulating 
the earliest stages of lymphoid stromal cell development, but 
whether CD11b+ myeloid cells drive the development HEV and/
or TLOs in chronic inlammation is not known (17).
How HEVs form during ongoing chronic diseases is diicult 
to dissect but insights to the stimuli and signaling pathways 
that control HEV neogenesis and function have come from 
experimental studies in mice. In experimental animals, organ-
ized lymphocytic iniltrates containing PNAd-expressing blood 
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vessels develop in exocrine tissue of the pancreas and thyroid 
in response to ectopic expression of homeostatic chemokines 
and cytokines that control LN development (115–118) and 
virus-induced autoantibody production in the salivary gland 
(119). However, as found in chronic diseases, the size, location, 
and composition of lymphoid iniltrates that develop at ectopic 
sites vary depending on the stimulus. For example, when LTα 
is expressed in pancreatic β cells PNAd expressing blood vessels 
are found inside the small lymphoid iniltrates that form around 
some islets (120). Development is independent of endogenous 
LTβ and dependent on signaling via the type I TNFR. However, 
the iniltrates comprise mainly memory T cells that express low 
levels of L-selectin, which may be due to the predominantly ablu-
minal expression of PNAd, which is unable to recruit L-selectin 
expressing lymphocytes (118). Co-expression of both LTα and 
LTβ and consequent LTβR signaling in the exocrine pancreas is 
required to develop large, organized lymphoid aggregates that 
contain HEV expressing PNAd at the luminal surface and, as 
in LNs, these ectopic TLOs are highly enriched in L-selectin-
expressing T and B lymphocytes. LTαβ expressing cells other than 
LTis drive TLO formation, such as T and B cells which upregulate 
LTαβ in response to ectopic expression of CCL21 and CXCL13, 
respectively (116). PNAd expressing, structurally distinct HEV 
develop within 5  days of transferring T cells to RAG-deicient 
mice expressing CCL21 under the thyroglubulin promoter and, 
as found in LN, HEV development is dependent on LTαβ–LTβR 
signaling and DCs (117, 121). As in LN, the development of 
PNAd expressing HEV in cytokine or chemokine-induced 
TLOs is stunted in mice deicient in either LTα or LTβ. PNAd-
expressing blood vessels lack the HEV-restricted sulfotransferase 
and, therefore, luminal expression of PNAd, and are lined with 
lat ECs typical of immature HEVs in LN unable to support 
high levels of lymphocyte traic. he lack of HEV maturation 
in the absence of LTα or LTβ correlates with and, most likely, 
contributes to the reduced size and cellularity of lymphoid 
iniltrates in these mice (118).
he development of PNAd-expressing HEV in mouse models 
of cytokine- or inlammation-induced cancer correlates with 
increased T cell iniltration and priming and reduced tumor 
growth (114, 122, 123). In tumor cell transplant models, PNAd 
expression is induced on tumor blood vessels by iniltrating 
tumor-speciic efector CD8+ T cells as well as NK cells (124). 
In marked contrast to HEV development in LN and TLO, PNAd 
expression is not dependent on LTβR signaling but is stimulated 
by CD8+ T and NK cell-derived LTα3 activation of TNFR. 
Interestingly, expression of the arrest chemokine CCL21 is not 
induced by the same stimuli that induce PNAd expression, but 
instead by IFN-γ released by activated T and NK cells. However, 
the tumor-associated HEVs are distinct from conventional 
mature HEVs in LN since PNAd expression is exceptionally low 
and the endothelial lining is lat, rather than the characteristic, 
LTβR-dependent cuboidal morphology found in LNs (50). 
Although comprising <10% of the tumor vascular network and 
lined by lat EC, these PNAd-expressing tumor blood vessels are 
functional in that they recruit naïve, L-selectin-expressing T cells 
from the bloodstream into the tumor where they are activated 
to kill tumor tissue (124). hese indings suggest that TNFR 
signaling in ECs stimulates the development of PNAd-expressing 
blood vessels resembling immature HEVs in LNs and that these 
vessels promote anti-tumour immunity by recruiting naïve T cells 
into cancerous tissues. his allows T cell priming and reactivation 
inside solid cancers, thus avoiding the dilution of tumoricidal T 
cells during redistribution from their LN site of priming via the 
eferent lymphatics and bloodstream (123).
he presence of HEV-containing TLO is highly correlated 
with active disease and for persistent infections such as H. pylori, 
TLOs in the gastric mucosa disappear when the infection is 
cleared (125). In the case of solid, vascularized cancers, the 
presence of TLO in resected solid cancers has been correlated 
with prolonged patient outcome following resection of the 
primary cancer in breast cancer (126, 127), melanoma (128, 
129), lung (130), and colorectal cancer, although in the latter 
case the correlation depends on the stage of the disease (131, 
132). In separate studies of lung cancer, mature DC containing 
TLO enriched in CD8+ efector memory T cells or expressing a 
LN-associated chemokine and adhesion molecule gene signature 
have both been correlated with improved patient outcome (133, 
134). Importantly however, the formation of TLO does not always 
indicate improved cancer patient outcome. In virus-induced 
hepatic cellular carcinoma, TLOs provide a cytokine-rich niche, 
which promotes the development and survival of malignant 
hepatocyte progenitors (11). he density of HEV alone was suf-
icient to predict patient outcome in breast cancer and melanoma 
(9, 10), indicating the critical role that HEVs play in orchestrating 
anticancer immunity. It will be interesting to determine the 
expression of other markers of HEV diferentiation such as 
MAdCAM-1, GlyCAM-1, GlcNAc6ST-2, and GlcNAc6ST-1 to 
further understand the precise roles of HEV development and 
maturation in protective immunity to clinical cancers.
Evidence of ongoing immune responses are seen inside TLOs; 
activation-induced cytidine deaminase is active in ectopic germi-
nal centers in salivary glands of Sjorgren’s syndrome patients (5) 
and T cell priming and epitope spreading occur in mouse models of 
multiple sclerosis and cancer (122, 135). In mice lacking all SLOs, 
Moyron-Quiroz and colleagues demonstrated that humoral and 
cellular immune responses develop in TLOs following inluenza 
infection (136). he formation of TLO in clinical conditions may, 
therefore, relect a lack of function in draining secondary LNs, 
which are no longer able to accept incoming antigen or antigen-
presenting cells or that SLOs are operating at maximal capacity. 
he formation of TLOs is thought to exacerbate autoimmune 
diseases, at least in part, because efector lymphocytes generated 
within the target organ will not be diluted out during transit from 
the normal LN site of priming. However, the impact of TLO will 
depend on the nature of the ongoing immune response to the 
autoantigen, pathogen, or cancer antigen, which may be protec-
tive (CD8+ T cells in cancer), inlammatory (h17 cells in autoim-
munity), or tolerance inducing (Foxp3+ regulatory T cells), and 
this may be regulated by the activation status of PNAd-expressing 
HEVs and additional factors such as chemokines. Further studies 
are required to understand exactly how ectopic HEVs are formed 
and their impact on diferent types of chronic diseases. Such stud-
ies may reveal therapeutic targets for intervention in autoimmune 
diseases and cancers.
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A Unifying Hypothesis of Hev Neogenesis
Extensive studies of SLOs and TLOs have shown that HEVs 
present as peripheral and/or mucosal addressin expressing 
blood vessels in which the endothelium is either characteristi-
cally cuboidal and illed with transmigrating lymphocytes or 
lat and, although PNAd-positive, lymphocyte-illed pockets 
are absent. Can we reconcile these divergent reports of HEV 
into a single, unifying model of HEV neogenesis in lymphoid 
and non-lymphoid tissues? Clues for this have come from 
studies in which cytokines ectopically expressed in pancreatic 
islets of mice stimulate the development of vascular addressin 
expressing blood vessels. Expression of LTα-induced PNAd and 
MAdCAM-1 on pancreatic blood vessels dependent on signaling 
through TNFR1 but the ECs are lat, do not express the HEV-
restricted sulfotransferase (HEC-6ST/GlcNAc6ST-2) and PNAd 
expression was located to the basolateral EC surface where, in 
LN, it does not support high levels of lymphocyte recruitment. 
Structurally distinct, PNAd-expressing blood vessels, similar 
to HEVs in LN, were only formed when LTα and LTβ were co-
expressed in pancreatic islets (137). Interestingly, LT-α drives the 
development of lat, PNAd-expressing blood vessels in mouse 
models of cancer which, although structurally similar to imma-
ture HEVs in LN, are able to recruit L-selectin-expressing T cells 
from the bloodstream via PNAd+ ligands indicating they are not 
completely immature (124).
LTα and LTαβ activate the classical NF-κB pathway charac-
terized by nuclear translocation of p50–RelA complexes. LTαβ 
also activates the alternative, non-canonical NF-κB pathway 
of NF-κB-inducing kinase (NIK)-dependent activation of IκB 
kinase (IKK)-α and nuclear translocation of p52–RelB complexes 
(138). Non-canonical NF-κB signaling plays a dominant role 
in the formation of HEVs in LNs since blockade of LTβR, but 
not TNFR, leads to loss of several HEV-speciic markers such 
as GlyCAM-1, MAdCAM-1, CCL21, and the HEV-restricted 
sulfotransferase, HEC-6ST/GlcNAc6ST-2 (58). In addition, 
PNAd-expressing blood vessels that develop in IKKα(AA) 
mutant mice where non-canonical NF-κB signaling is defective 
lack GlyCAM-1 and HEC-6ST (49). Conversely, mice lacking 
full-length p100 protein, resulting in constitutively active p52, 
develop PNAd-positive HEVs in the spleen (139). he key event 
in non-canonical NF-κB activation is signal-induced protein sta-
bilization of NIK that is normally degraded by a ubiquitin ligase 
complex comprising TRAF2, TRAF3, and cIAP1/2 (140, 141). 
LTβR ligation sequesters this NIK-targeting destruction complex 
leading to NIK accumulation. Importantly, signal-induced NIK 
stability is transient (142), suggesting that continual activation 
of the LTβR is required to maintain functional NIK expression 
levels and hence, sustain the activity of the non-canonical NF-κB 
pathway.
It is proposed that the development of HEVs is dissected into 
at least two distinct stages based on NF-κB signaling in blood 
vessel ECs (Figure  2). he irst stage is driven by LTα-TNFR 
classical NF-κB signaling and generates MAdCAM-1-expressing 
HEV lined with lat, PNAd-expressing ECs. he second stage is 
driven by sustained LTβR non-canonical NF-κB signaling and 
induces the development of fully mature, PNAd-expressing 
HEVs lined by HECs and containing lymphocyte-illed pockets. 
However, these two stages may be not always be clearly deline-
ated because there is overlap between classical and non-canonical 
NFκB signaling in blood ECs. For example, classical RelA/NF-κB 
signaling by TNFα, LTα, or LTαβ in EC cultured from human 
and mouse tissues induces expression of MAdCAM-1 protein 
and expression of the gene encoding HEC-6ST, which generates 
the PNAd epitope in LN HEVs (33–35, 143). However, LTβR 
signaling in isolated human EC has not been reported to induce 
the expression of PNAd modiied glycoproteins (143). It is known 
that classical NF-κB-dependent signaling in human EC inhibits 
non-canonical NF-κB signaling (144). he outcome of LTβR 
signaling in ECs will, therefore, depend on the balance between 
classical and non-canonical NF-κB signaling. Recent studies 
have demonstrated that endothelial diferentiation is regulated 
by components of the basal lamina (145). As in other types of 
postcapillary venule, structural support to the endothelial lining 
of HEV is provided by the basal lamina, which is known to regu-
late NF-κB signaling (146). Further studies on isolated blood ECs 
may identify the stimuli and signaling pathways that stimulate 
the synthesis of HEV-restricted PNAd-modiied glycoproteins 
thereby controlling HEV neogenesis.
THeRAPeUTiC STRATeGieS TO 
CONTROL Hev NeOGeNeSiS AND 
FUNCTiON
If HEVs in TLO are critical to exacerbation of autoimmune 
diseases by allowing activation of tissue destroying lymphocytes 
within target tissues, can the development of HEVs be prevented? 
Since HEVs in SLOs are important for generating protective 
immunity to infection any such therapy would need to be targeted 
to TLO. Intuitively, this will require the identiication of markers 
or signaling pathways in ectopic HEVs that are not shared by 
HEVs in LN. One candidate is TNFR signaling that is not required 
for the development or maintenance of HEVs in LN (58) but has 
been shown to induce PNAd-expressing ectopic HEVs able to 
recruit naïve T lymphocytes, at least in cancer (124). It is pos-
sible that the success of anti-TNF-α or TNFRII-Ig (Etanercept) 
therapies in rheumatoid arthritis patients may depend, in part, 
on reversing or blocking blood vessel diferentiation toward an 
HEV-like phenotype. he formation of HEVs in cancerous tissues 
in the absence of TLO correlates with reduced tumor progression 
in experimental animals; HEV neogenesis may, therefore, be a 
possible therapy to control cancer growth but it is not clear how 
this would be achieved. Clinical and experimental data indicate 
that tumor blood vessels are poor at recruiting cytotoxic, efector 
T lymphocytes and present an immune checkpoint that limits 
efective immunotherapy (147). Several diferent strategies are 
being considered to achieve this including targeted delivery of 
TNF-α to tumor blood vessels, which may induce the develop-
ment of PNAd-expressing blood vessels although this was not 
determined (148). Approaches to induce HEV-containing TLO 
formation in cancers are also being considered but it is worth 
bearing in mind that TLOs, like SLOs, could be sites of tolerance 
induction and, therefore, may limit efective antitumor immunity. 
he full impact of HEVs and/or TLO may only be revealed when 
FiGURe 2 | The development of ectopic high endothelial venules (Hevs). Top: diagrammatic representation of blood vasculature in non-lymphoid organs and 
the location of postcapillary venules. Bottom (left): blood vessels in acutely inlamed tissues do not express vascular addressins but are able to recruit activated 
lymphoid cells. (Middle) TNFα, LTα, or LTαβ expressing T or NK cells recruited by inlamed blood vessels induce the expression of peripheral node addressin (PNAd) 
(and/or MAdCAM-1) in blood vessels lined with lat endothelial cells (ECs) by stimulating classical NF-κB (RelA) signaling in ECs. (Right) Sustained contact between 
LTαβ expressing activated lymphoid cells and PNAd expressing lat EC induces LTβR-dependent non-canonical NF-κB (RelB) signaling in ECs, which allows the full 
maturation of PNAd-expressing HEV lined with cuboidal ECs illed with transmigrating lymphocytes. It is not known if the recruitment of ibroblast reticular cells into 
the perivascular sheath surrounding HEV is driven by LTβR signaling in ECs or perivascular cells or both.
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highly immunosuppressive cells such as Foxp3+ Tregs or myeloid-
derived suppressor cells are depleted allowing efector T cells to 
exit TLO, iniltrate, and kill cancerous tissues (114, 149, 150). It 
will be important to determine which immune cells are recruited 
by cancer-associated HEVs to dissect their impact on cancer 
immunity. Further studies are required to determine the extent 
and role of HEV development in clinical cancers.
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